Objectives-To use subharmonic imaging (SHI) to depict the vascularity of pancreatic masses compared to contrast-enhanced endoscopic ultrasound (EUS) and pathologic results.
W ith 53,070 new cases expected in 2016, pancreatic adenocarcinoma is among the most common cancers diagnosed in the United States. 1 It is the fourth leading cause of cancer-related death in both men and women, with nearly 41,780 deaths this year and 5-year survival rates at around 5%. [1] [2] [3] One of the reasons that the mortality rate nearly parallels the incidence is that only 15% to 20% of patients are considered resectable at the time of diagnosis. Another 20% to 25% have locally advanced disease that is not amenable to surgical resection, and nearly half of patients present with metastatic disease (mainly to the liver). 1, 4 Despite the "curative" intent of treatment for patients who present with surgically amenable pancreatic cancer, even when undergoing resection followed by adjuvant systemic therapy (with or without radiation), their median overall survival is still only 15 months. 5 Although endoscopic ultrasound (EUS) is frequently the imaging mode used for managing pancreatic cancer, 6 to date there are no established guidelines for screening patients at high risk for developing pancreatic cancer 4, 6 with tests that are cost-effective and have high sensitivity and specificity. Hence, the long-term goal of this project is to develop such a screening technique based on contrast-enhanced ultrasound (CEUS) imaging.
Although contrast-enhanced EUS is a widely used technology in Europe and Asia, it is still not a standard of care in the United States, in part because of the lack of approved contrast agents and contrast-specific EUS imaging equipment. 6 There are currently 3 ultrasound contrast agents approved by the United States Food and Drug Administration for cardiologic and radiologic applications (the latter involves only 1 contrast agent, which was approved as recently as April 2016). These agents consist of encapsulated gas microbubbles (<8 lm in diameter) and have been shown to produce marked nonlinear signals at higher acoustic pressures (>0.5 MPa), which are used in contrast-specific CEUS imaging modes. [7] [8] [9] Harmonic imaging (HI), transmitting at the fundamental frequency (f 0 ) and receiving at the second harmonic (2f 0 ), is one such CEUS imaging technique that is available on many commercial ultrasound scanners. However, HI is limited by reduced blood-to-tissue contrast caused by second-harmonic generation in tissue. 10 Hence, subharmonic imaging (SHI), transmitting at the fundamental frequency (f 0 ) and receiving at the subharmonic (f 0 /2), becomes an attractive alternative contrast-specific imaging mode (even with the reduced axial resolution relative to HI) because of a lack of subharmonic signals generated by the tissue. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Contrast studies of women with breast lesions (in up to 134 patients) have demonstrated that SHI can detect the neovascularity associated with tumors with greater sensitivity than HI. [12] [13] [14] Moreover, a study in 45 patients with liver disease has shown that SHI can be successfully performed in the abdomen at depths up to 12 cm. 15 Thus, this pilot study investigated the feasibility of using contrast-enhanced transabdominal SHI to depict pancreatic masses in patients scheduled for an endoscopically guided biopsy of a pancreatic mass. Results were compared to contrast-enhanced EUS as well as to pathologic results.
Materials and Methods

Patients
This pilot study enrolled 16 patients scheduled for an EUS-guided biopsy of a mass located in the head of the pancreas. The study was conducted during a 12-month period from May 2014 to May 2015. Before enrollment, each patient gave written informed consent. The study was approved by the university's Institutional Review Board and was compliant with the Health Insurance Portability and Accountability Act.
This study was supported by Lantheus Medical Imaging (North Billerica, MA), which provided the ultrasound contrast agent used. However, the authors of this article had sole control of the data generated by this trial and the information provided for publication.
Data Acquisition
A LOGIQ 9 scanner (GE Healthcare, Milwaukee, WI) with a 4C transducer was modified to operate in dual 4.0-MHz grayscale and pulse inversion grayscale SHI modes (to allow for simultaneous depiction of anatomy and contrast-enhanced vascularity), with the latter mode transmitting 4-cycle pulses at 2.5 MHz and receiving with a 1-MHz wide bandpass filter centered at 1.25 MHz. 16 A 0.5-mm needle hydrophone (Precision Acoustics, Ltd, Dorchester, England) was used to establish that the maximum acoustic output pressure level was 3.34 MPa (peak to peak equivalent to a mechanical index of 0.8). 15 However, based on our previous experiences, the acoustic output power for SHI was kept below 25% (to minimize bubble destruction). 17 The remaining parameters used for image acquisition were selected on an individual basis to optimize image quality by a sonographer with more than 15 years of experience (M.S. or T.F.).
The midline of the pancreatic mass was located (using conventional, individually optimized grayscale imaging) while also including some adjacent normal pancreatic tissue in the field of view. Before injection, the lesion size (height, length, and width) was measured.
For CEUS, the midline imaging plane was maintained and the ultrasound contrast agent Definity (Lantheus Medical Imaging) was injected (dose, 0.6-0.8 mL) through an antecubital vein, followed by a 10-mL saline flush. The Food and Drug Administration has approved Definity, which consists of phospholipid-shelled octafluoropropane microbubbles of approximately 1.1 to 3.3 lm in diameter, 23 for use in echocardiography, and it was used off-label in this study. The complete contrast wash-in and wash-out was imaged in the SHI mode, and a digital clip was acquired (typically 45-75 seconds) for subsequent offline analysis.
Next the patients were intubated with a radial echoendoscope (GF-UTC180; Olympus Corporation, Tokyo, Japan) connected to a ProSound SSD a-10 scanner (Hitachi Aloka, Tokyo, Japan) as part of their standard of care. The echoendoscope was advanced until the target lesion was identified and its features fully characterized for clinical purposes. Before the biopsy, stateof-the art contrast harmonic EUS (transmitting at 4.7 MHz and receiving at 9.4 MHz) was performed at low acoustic power (mechanical index < 0.25) after a second injection of Definity (dose, 0.3-0.4 mL). 24, 25 The time between injections was at least 10 minutes to allow the agent to clear the blood pool. A 1-to 2-minute digital clip of the contrast wash-in and wash-out was acquired for comparison to SHI and to the biopsy results.
Data Analysis
To quantify the ability of both imaging modes to delineate between the mass and the normal pancreas, the contrast-to-tissue ratio (CTR) at peak contrast enhancement was used. The CTR is defined as
where l t and l n represent the mean image signal strength in the target (here the mass) and within normal pancreatic tissue, respectively, and r 2 t and r 2 n represent the variance in the respective regions calculated based on region of interest (ROI) selections. For all patients and both imaging modes, a circular ROI (10 mm in diameter) was placed in the mass and compared (one at a time) to 2 ROIs placed within the normal pancreatic tissues using ImageJ (version 1.48; National Institutes of Health, Bethesda, MD) and Equation 1. Likewise, a 10-mm ROI was placed on an adjacent large normal vessel outside the mass and compared to the same 2 pancreatic tissue ROIs as described above to evaluate the impact of the contrast concentration. Results were compared by location, by imaging mode, and by pathologic findings with unpaired t tests, assuming a 5% significance level (Stata 12; Stata Corp, College Station, TX).
Next, 2 board-certified gastroenterologists specializing in EUS (with 11 and 17 years of experience, respectively) and 2 board-certified body imaging radiologists (with 14 and 19 years of experience) blinded to the pathologic findings independently evaluated the realtime CEUS clips (ie, 2 assessments for contrast EUS and 2 for SHI). The 4 physicians all had 10 or more years of experience in CEUS. Offline diagnoses were made on the basis of a 5-point scale: 1, benign; 2, probably benign; 3, indeterminate; 4, probably malignant; and 5, malignant, with hypoenhancing lesions considered more likely to be malignant, whereas isoenhancing and hyperenhancing masses were considered more benign characteristics. 25, 27 The vascular density and morphologic characteristics relative to the surrounding normal pancreatic tissues were also considered. The accuracy of the imaging diagnoses was analyzed by receiver operating characteristic (ROC) analyses. 28 Differences between ROC curves were tested by computing Mann-Whitney statistics, whereas inter-reader agreement was assessed by calculating the j statistic (using Stata 12).
Results
One patient dropped out before imaging was initiated, leaving 15 patients with an average lesion diameter of 3.07 cm (range, 1.39-6.37 cm) who completed this pilot study. The mean age of the patients (9 female and 7 male) participating in the study was 67 years (range, 27-88 years; Table 1 ) The pathologic reference standard found 11 adenocarcinomas, 1 gastrointestinal stromal tumor with pancreatic infiltration, and 3 benign masses (Table 1) . Marked subharmonic signals and reasonable tissue suppression were obtained in all patients, with intratumoral blood flow clearly visualized with SHI, as demonstrated in the example of Figure 1 . Although larger vessels external to the pancreatic mass were seen with both EUS and SHI, smaller neovessels in the mass were more easily visualized with SHI, in spite of the reduced axial resolution and deeper scanning depths of SHI relative to EUS (compare Figure 1, B and D) . Moreover, the larger field of view associated with SHI was particularly useful in depicting anatomic relationships on a greater scale than EUS, such as the gastric inflow into a gastrointestinal stromal tumor with pancreatic infiltration (Figure 2 ). Significantly greater CTRs were obtained in the pancreatic masses with SHI than with EUS, whereas there were no differences in CTRs when comparing the enhancement of the adjacent large normal vessels (Table 2 ). Together, these results indicate that the contrast concentration is not a factor and that transabdominal SHI is able to depict smaller neovessels inside a pancreatic mass better than contrast EUS (as also demonstrated in Figure 1 ). When the CTR values were grouped by pathologic results into benign and malignant cases, no statistical differences were found for either imaging mode (mean 6 SD, 0.60 6 0.88 versus 0.64 6 0.91 and 1.25 6 2.03 versus 1.63 6 1.49 for EUS and SHI, respectively; P > .60). The diagnostic accuracies for contrast EUS and SHI (in the form of the area under the ROC curve [A z ]) were quite low ( Table 3) . The A z of one of the EUS readers was lower than those based on SHI. No other A z comparisons were significant (P > .05). The inter-reader agreement was greater for SHI than for EUS (Table 3) .
Discussion
In this pilot study, transabdominal SHI improved (quantified via the CTR metric) the depiction of contrast microbubbles in the small angiogenic neovessels associated with pancreatic masses compared to contrast EUS ( Figure 1 and Table 2 ) allowing the tortuous morphologic characteristics of tumor angiogenesis 7 to be visualized in greater detail. Moreover, the increased field of view with SHI was shown to be useful for providing a detailed overview of the vascular supply to pancreatic lesions (compare Figure 2) . These results are in agreement with our prior experiences in breast imaging, in which SHI was found to detect tumor neovascularity with greater sensitivity than HI (ie, the technology imbedded in contrast EUS). [12] [13] [14] An in vivo SHI CTR value of 5.74 6 1.92 was previously reported by Eisenbrey et al, 18 which was greater than the 1.71 6 1.63 measured in this pilot study. However, the former CTR value was obtained in an open abdomen canine renal model, and the discrepancies observed are most likely due to the attenuation and contrast concentration (ie, flow) differences between a human pancreas and a dog kidney. Thus, contrast-enhanced SHI appears to depict pancreatic masses better than contrast EUS (at least for lesions located in the head of the pancreas).
The diagnostic accuracy of SHI and contrast EUS was rather low (A z < 0.55) in this small pilot study of 15 patients (Table 3) . Results from this study also showed greater agreement between readers of SHI compared to EUS (Table 3) . Although this article is (to the best of our knowledge) the first report on SHI of pancreatic cancers in patients, contrast EUS has been studied more extensively. One recent study of 147 pancreatic masses imaged with contrast EUS reported sensitivity of 94% and specificity of 71%. 25 A meta-analysis of 12 studies involving 1139 patients found similar diagnostic accuracy of 0.97 based on ROC analysis, with pooled sensitivity and specificity of 94% and 89%, respectively. 27 Most likely, the small sample size in this pilot study accounts for most of these differences.
Nonetheless, these results indicate that the clinical niche for SHI may be earlier in the management of pancreatic lesions. Currently, contrast-enhanced computed tomography (CT) is used as the first-line imaging modality for the pancreas. 29 However, ultrasound microbubble-based contrast agents are exceptionally safe vascular tracers and, unlike CT with contrast, have very few contraindications (typically involving allergies to the gas encapsulation material) and involve no radiation. Moreover, the higher frame rates (ie, temporal resolution) of ultrasound (including SHI) relative to CT will permit better quantification of blood flow kinetics. Finally, the sensitivity and specificity for CT detection of pancreatic masses is reported to range from 68% to 86% and from 50% to 64%, making it lower than that of contrast EUS reported in the literature (94% and 89%, respectively). 27, 29 Consequently, SHI may be a better imaging mode for the initial assessment of pancreatic lesions, followed by a biopsy under EUS guidance (if required), and future studies should compare SHI and CT for this application.
Additionally, the improved depiction of pancreatic tumor neovascularity may be useful in determining whether a lesion is resectable as well as monitoring the response to treatment in patients not eligible for surgical resection. If there are no distant metastases, the decision to resect a pancreatic tumor or not is largely driven by which vessels are involved (most critically the superior mesenteric artery and vein as well as the celiac and hepatic arteries). 29, 30 These assessments can sometimes be difficult to resolve with CT or magnetic resonance imaging, and CEUS might improve specificity. This issue will be a topic for future investigations.
In conclusion, contrast-enhanced SHI can potentially be used as an imaging tool for identifying the vascularity of pancreatic masses. In this pilot study, SHI showed improved tumoral CTRs relative to contrast EUS. However, the diagnostic accuracy of both contrast EUS and transabdominal SHI for assessment of pancreatic masses was quite low in this small population. Although the long-term aim of this project is to develop a CEUS-based screening technique for patients at high Data are presented as mean 6 SD. risk of developing pancreatic adenocarcinoma, it is first necessary to establish the utility of CEUS and SHI in characterizing pancreatic lesions, before beginning a trial to investigate whether these techniques aid in lesion detection. Hence, future efforts should initially be directed at comparing CT and SHI for imaging pancreatic masses or for monitoring the treatment response of pancreatic adenocarcinoma with SHI.
